CCCC - CCCC C4 Therapeutics up more than 20% on annual report filing
2024-02-22 14:04:23 ET
DENVER, Colo., Feb 22, 2024 ( 247marketnews.com ) – ( NASDAQ:CCCC ) discussed in this article. CCCC just hit a high of $8.72 with more than usual volume of just over 4 million after filing the annual report.
About C4 Therapeutics
C4 Therapeutics (C4T) (Nasdaq: CCCC) is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patients’ lives. C4T is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO ® platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, drug undruggable targets and improve patient outcomes. For more information, please visit www.c4therapeutics.com .
The post CCCC C4 Therapeutics up more than 20% on annual report filing first appeared on 24/7 MarketNews .
For further details see:
CCCC C4 Therapeutics up more than 20% on annual report filing